161 related articles for article (PubMed ID: 30673070)
21. Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
Nellessen CM; Janzen V; Mayer K; Giovannini G; Gembruch U; Brossart P; Merz WM
Arch Gynecol Obstet; 2018 Feb; 297(2):281-284. PubMed ID: 29110117
[TBL] [Abstract][Full Text] [Related]
22. Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
Breccia M; Vignetti M; Annibali O; Cottone F; Luppi M; Borlenghi E; Rodeghiero F; Efficace F
Br J Haematol; 2020 Sep; 190(5):e304-e307. PubMed ID: 32557531
[No Abstract] [Full Text] [Related]
23. CPSF6-RARG-positive acute myeloid leukaemia resembles acute promyelocytic leukaemia but is insensitive to retinoic acid and arsenic trioxide.
Li J; Yan WZ; Bai LH; Jiang YF; Peng HL; Shen JK; Li RJ
Pathology; 2023 Apr; 55(3):407-412. PubMed ID: 36241556
[No Abstract] [Full Text] [Related]
24. [Effect of Chromosomal Karyotype on the Prognosis of Patients with Acute Promyelocytic Leukemia in Condition of the Maintenance Treatment Based on Arsenic Trioxide].
Lai BB; Mu QT; Zhang YL; Chen Y; Ouyang GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1380-1386. PubMed ID: 31607287
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Kayser S; Schlenk RF; Lebon D; Carre M; Götze KS; Stölzel F; Berceanu A; Schäfer-Eckart K; Peterlin P; Hicheri Y; Rahme R; Raffoux E; Chermat F; Krause SW; Aulitzky WE; Rigaudeau S; Noppeney R; Berthon C; Görner M; Jost E; Carassou P; Keller U; Orvain C; Braun T; Saillard C; Arar A; Kunzmann V; Wemeau M; De Wit M; Niemann D; Bonmati C; Schwänen C; Abraham J; Aljijakli A; Haiat S; Krämer A; Reichle A; Gnadler M; Willekens C; Spiekermann K; Hiddemann W; Müller-Tidow C; Thiede C; Röllig C; Serve H; Bornhäuser M; Baldus CD; Lengfelder E; Fenaux P; Platzbecker U; Adès L
Haematologica; 2021 Dec; 106(12):3100-3106. PubMed ID: 34047178
[TBL] [Abstract][Full Text] [Related]
26. Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Rahmé R; Ades L; Thomas X; Guerci-Bresler A; Pigneux A; Vey N; Raffoux E; Castaigne S; Spertini O; Wittnebel S; Marolleau JP; Damaj G; Bordessoule D; Lejeune J; Chevret S; Fenaux P
Haematologica; 2018 Nov; 103(11):e519-e521. PubMed ID: 29794147
[No Abstract] [Full Text] [Related]
27. [Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion].
Tøstesen M; Østgård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336300
[TBL] [Abstract][Full Text] [Related]
28. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
29. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).
Fujita H; Ishikawa Y; Yokoyama Y
Int J Hematol; 2020 Jun; 111(6):747-760. PubMed ID: 32347422
[No Abstract] [Full Text] [Related]
30. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
31. Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
Testi AM; Mohamed S; Diverio D; Piciocchi A; Menna G; Rizzari C; Timeus F; Micalizzi C; Lo Nigro L; Santoro N; Masetti R; Micheletti MV; Ziino O; Onofrillo D; Ladogana S; Putti C; Pierani P; Arena V; Zecca M; Foà R; Locatelli F
Br J Haematol; 2021 Oct; 195(2):278-283. PubMed ID: 34145572
[No Abstract] [Full Text] [Related]
32. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
[TBL] [Abstract][Full Text] [Related]
33. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL
Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321
[TBL] [Abstract][Full Text] [Related]
35. Strategies for the treatment of acute promyelocytic leukemia.
Frankfurt O; Tallman MS
J Natl Compr Canc Netw; 2006 Jan; 4(1):37-50. PubMed ID: 16403403
[TBL] [Abstract][Full Text] [Related]
36. [Arsenic efficient in acute promyelocytic leukemia].
Lehmann S; Paul C
Lakartidningen; 1999 Dec; 96(50):5626-8. PubMed ID: 10643228
[TBL] [Abstract][Full Text] [Related]
37. Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia.
Hickey E; Clemons B; Griffin S; Cox J; Sutphin S; Ramlal R; Benitez L
Leuk Lymphoma; 2019 Dec; 60(14):3557-3560. PubMed ID: 31294640
[No Abstract] [Full Text] [Related]
38. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
39. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
Hazenberg CLE; Diepstra A; Santing M; Huls GA; Ammatuna E
Ann Hematol; 2022 May; 101(5):1133-1134. PubMed ID: 34750663
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
